Dry AMD Symposium 2

Related

• 

  Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

  W. Lloyd Clark, MD, FASRS

  Updates from the Field

  2022

• 

  Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial

  Peter A. Campochiaro, MD

  Updates from the Field

  2021

• 

  Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

  David R Lally, MD

  Annual Meeting Talks

  2021